Thermo Scientific™

Lab Vision™ HER-2/c-erbB-2/neu (Phospho-specific) Ab-18, Mouse Monoclonal Antibody

Related applications:

Anatomical Pathology

Provide accurate, reproducible results with the Thermo Scientific™ HER-2/c-erbB-2/neu (Phospho-specific) Ab-18, Mouse Monoclonal Antibody.
Back to top
c-erbB-2 (HER-2/neu) is a 185 kDa receptor tyrosine kinase belonging to the epidermal growth factor receptor family, which also includes EGFR (HER-1), c-erbB-3 (HER-3), and c-erbB-4 (HER-4). Amplification of the HER-2 gene with overexpression of the protein occurs in 20-30% of breast cancers, and tumor progression in mammary cancer is associated with elevated levels of tyrosine-phosphorylated neu and erbB-3. Tyr1248 is the phosphorylation site that is most tightly linked to oncogenic transformation and coupling to the ras/MAP kinase signaling pathway. Cases of invasive breast carcinoma with the phosphorylated receptor have displayed aggressive clinicopathological features and adverse prognoses. Activation of HER-2 is frequent in ductal carcinoma in situ suggesting that HER-2 signaling plays a critical role in the early stages of breast tumorigenesis.

Host Species: Mouse

Clone: PN2A

Isotype: IgG1

Species Reactivity: Human and Rat. Others not tested.

Epitope: aa 1242-1255 with pTyr

Immunogen: Tyrosine-phosphorylated synthetic peptide corresponding to aa 1242-1255 [Lys-TAENPE-pY-LGLDVPV] from the C-terminus of human HER-2 protein (P-Tyr1248)

Molecular Weight: 185 kDa

Positive Control: EGF-treated SKBR-3 cells. About 5% of breast CA are positive for phospho-HER-2/c-erbB-2/neu oncoprotein.

Cellular Localization: Membrane

Recommended for:

  • Immunohistochemistry
  • Western Blotting
  • Immunofluorescence
  • Immunoprecipitation (Not verified)
  • Flow Cytometry (Not verified)

Note:

USA: RUO; Int'l: RUO

General References:

1. Xu W et al. Cancer Research 200363:7777-7784.

10. DiGiovanna MP et al. Oncogene 199817:1877-84.

11. Christensen JG et al. Clinical Cancer Research 20017:4230-4238.

12. Brandt BH et al. FASEB J 199913:1939-49.

13. DiGiovanna MP and Stern DF. Cancer Research 199555:1946-55.

14. DiGiovanna MP et al. Cancer Research 200262:6667-6673.

2. DiGiovanna MP et al. Br J Cancer 199674(5):802-6.

3. Ramsauer VP et al. J Biol Chem 2003278(32):30142-30147.

4. Klapper LN et al. Adv Cancer Res 200077:25-79.

5. Hayes DF et al. Semin Oncol 200229(3):231-45.

6. Siegel PM et al. EMBO J 199918(8):2149-64.

7. Thor AD et al. J Clin Oncol 200018(18):3230-9.

8. Ouyang X et al. Mol Cell Biochem 2001218(1-2):47-54.

9. Ouyang X et al. Mol Diagn 20016(1):17-25.